Skip to content

Halozyme Therapeutics

US · HALO #1276 by market cap Listed 1970
91.35 -1.69 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.2 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
113.97% -0.20pp
Institutions
912 -4
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund86.27%
Hedge Fund11.64%
Public Company7.63%
Private Company3.56%
Government Pension Fund2.46%
Sovereign Wealth Fund1.30%
Individual/Insider1.05%
Family Office/Trust0.63%
Insurance Company0.33%

Top holders as of 2026-09-30

BlackRock 11.99% · 13.67M sh
Vanguard Capital Management, LLC 5.12% · 5.84M sh
State Street Global Advisors 4.44% · 5.06M sh
Vanguard Portfolio Management, LLC 4.37% · 4.99M sh
Two Sigma Investments, LP 3.09% · 3.52M sh
D. E. Shaw & Co., L.P. 2.96% · 3.37M sh
Invesco Ltd. 2.58% · 2.94M sh
William Blair Investment Management, LLC 2.28% · 2.59M sh
Boston Partners Global Investors, Inc. 2.42% · 2.76M sh
Geode Capital Management, LLC 2.12% · 2.41M sh
Snyder Capital Management, L.P. 2.11% · 2.40M sh
Morgan Stanley 1.98% · 2.24M sh
Congress Asset Management Company, LLP 2.00% · 2.28M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 26 buys · 24 sells

NameRoleStake
Helen Torley Chief Executive Officer 0.67%
Michael LaBarre Former Chief Technology Officer 0.15%
Mark Snyder Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary 0.04%
Matthew Posard Independent Director 0.04%
Nicole LaBrosse Former Chief Financial Officer 0.03%
Bernadette Connaughton Independent Director 0.03%
Jeffrey Henderson Independent Chairperson 0.03%
Akiko Moni Miyashita Former Independent Director 0.02%
Barbara Duncan Independent Director 0.01%
Mahesh Krishnan Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-07 Helen Torley Chief Executive Officer Derivative Exercise and Sale -60,000 $18.41–113.69
2026-09-30 James Daly Director Other Acquisition +1,169 --
2026-09-30 James Daly Director Other Derivative Acquisition +1,775 $106.94
2026-09-30 Matthew Posard Independent Director Automatic Disposition -5,230 $107.17–110.04
2026-09-15 Matthew Posard Independent Director Automatic Disposition -18,996 $106.13–108.99
2026-09-10 Helen Torley Chief Executive Officer Derivative Exercise and Sale -60,000 $18.41–108.67
2026-08-31 Dannielle Appelhans Director Other Acquisition +1,161 --
2026-08-31 Dannielle Appelhans Director Other Derivative Acquisition +1,778 $107.72
2026-08-18 Helen Torley Chief Executive Officer Derivative Exercise and Sale -60,000 $18.41–107.77
2026-08-09 Bernadette Connaughton Independent Director Automatic Disposition -1,626 $102.80
2026-07-07 Helen Torley Chief Executive Officer Derivative Exercise and Sale -1,923 $12.07–80.19
2026-06-30 David Ramsay President of Drug Delivery Other Derivative Acquisition +16,232 --
2026-06-30 David Ramsay President of Drug Delivery Other Derivative Acquisition +39,823 $77.01
2026-06-30 Bernadette Connaughton Independent Director Automatic Disposition -1,625 $76.40–77.21
2026-06-30 Darren Snellgrove Senior Vice President Other Derivative Acquisition +41,554 --
2026-06-30 Darren Snellgrove Senior Vice President Other Derivative Acquisition +127,432 $77.01
2026-06-29 David Ramsay President of Drug Delivery Derivative Exercise and Sale -5,408 $78.27
2026-06-29 David Ramsay President of Drug Delivery Derivative Exercise and Retained +4,592 --
2026-06-28 Mahesh Krishnan Independent Director Derivative Exercise and Sale -7,304 $38.46–75.00
2026-06-11 Mark Snyder Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary Derivative Exercise and Sale -2,715 $69.50

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Halozyme Therapeutics discussion 0 comments

Add a comment